Trichostatin A (TSA)

目录号：S1045

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA)是一种HDAC抑制剂，无细胞试验中IC50为1.8 nM左右。

规格 价格 库存 购买数量  
RMB 2022.93 现货
RMB 3660.93 现货
RMB 7125.3 现货
有超大折扣
大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户使用Selleck该产品发表文献67篇：

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 Trichostatin A (TSA)是一种HDAC抑制剂，无细胞试验中IC50为1.8 nM左右。
靶点
HDAC [1]
(Cell-free assay)
~1.8 nM
体外研究

Trichostatin A 抑制八种乳腺癌细胞系，包括MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, 和 SK-BR-3增殖，平均IC50为124.4 nM (范围为26.4-308.1 nM),作用于表达ERα的细胞系比作用于表达 ERα阴性的细胞系更有效。Trichostatin A作用于全部乳腺癌细胞系，抑制HDAC活性，平均IC50为 2.4 nM (范围为0.6-2.6 nM), 产生显著的组蛋白 H4高度乙酰化。[1]与 Trapoxin (TPX) 和 Chlamydocin 有效抑制HDAC1 或 HDAC4而不是 HDAC6不同，Trichostatin A 抑制这些HDACs，且抑制程度相似， IC50 分别为6 nM, 38 nM, 和8.6 nM。[2] Trichostatin A (100 ng/mL) 作用于MIA PaCa-2细胞，通过招募p300和 PCAF进入Sp1-NF-Y HDAC复合体，而诱导转化生长因子βⅡ型受体(TβRII) 表达，复合体与TβRII 启动子的DNA片段结合，伴随着Sp1乙酰化，且与复合体相关的HDAC数理全部降低。[4]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 NXHmcoIyTnWwY4Tpc44hSXO|YYm= MYWwMlfPxE1? MVuyOIg> M2jEZ4V1cGGwb3y= M2fkUoVvcGGwY3XzJGVP[UNiYXPleJlt[XSrb36gZY5lKGmwY4LlZZNmeyCHTnHDJIFjfW6mYX7j[UBqdiC2aHWgeI91[WxiY3XscEBtgXOjdHWgZY5lKGG2IITo[UBk\WyuIIP1doZi[2V? NULUVJduOjV5OEewO|k>
TE13 MVzGeY5kfGmxbjDBd5NigQ>? M3XtfFAvO87:TR?= M{LXTFI1cA>? NI\SUJR2eC2{ZXf1cIF1\XNiUlHTV2Y2SSCuZY\lcC=> MmXnNlU2Pzl4NkW=
TE13 MoKxRZBweHSxc3nzJGF{e2G7 NY\TSHBuOC5|zszN NGH4ZYszPGh? MnXrbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdg>? NF7n[JAzPTV5OU[2OS=>
MEFs MornSpVv[3Srb36gRZN{[Xl? NFf6PY82|ryP M{e1e|E3cA>? NH3LUW1qdmO{ZXHz[ZMhfGinIFXQSWMh[XS2YXPocYVvfCxiVHnyJIRmdGm4ZYL5JIFv\CC2aHWg[YZncWOrZX7jfUBw\iCyZXTld5RidCCob4LtZZRqd25? MoTkNlU1QDJ4M{S=
SW480  NGnGVY1HfW6ldHnvckBCe3OjeR?= NIf3ZWYxNjIQvF2= MmTVOFhp MWrEUXNQ MlvRdoV3\XK|ZYOgSW1V M{LtbVI2PDN2OUm3
PC3  NGH6SIFHfW6ldHnvckBCe3OjeR?= NX\uVVZ2OC5zzszN MYe0PIg> M4LhZWROW09? NVHCeVVTemW4ZYLz[ZMhTU2W MoHCNlU1OzR7OUe=
SW480  Mn3TSpVv[3Srb36gRZN{[Xl? NWfSWmh1OC5zzszN NX;jT29iPDiq MYDEUXNQ NFj3SlNifHSnboXheIV{KGmwdnHzbY9vKGGwZDDtbYdz[XSrb36= NYP3TJNuOjV2M{S5PVc>
PC3  MoXvSpVv[3Srb36gRZN{[Xl? NIKxVIgxNjIQvF2= MX20PIg> MnzVSG1UVw>? NEDDeGlifHSnboXheIV{KGmwdnHzbY9vKGGwZDDtbYdz[XSrb36= MVeyOVQ{PDl7Nx?=
SW480  NH7hfJJHfW6ldHnvckBCe3OjeR?= M1vNS|AvOc7:TR?= NXnMWVU2PDiq NV\QNYU{TE2VTx?= NFzLVVlqdmS3Y3XzJIlv[3KnYYPlJI9nKEiGQVOxJIFv\CCKRFHDNkBwdiCVbIXnJIdmdmW|IIDyc41wfGW{ M4KwflI2PDN2OUm3
PC3  M{WxSWZ2dmO2aX;uJGF{e2G7 NUm0VZBZOC5zzszN MUO0PIg> MXfEUXNQ NFfXN41qdmS3Y3XzJIlv[3KnYYPlJI9nKEiGQVOxJIFv\CCKRFHDNkBwdiCVbIXnJIdmdmW|IIDyc41wfGW{ MmrQNlU1OzR7OUe=
A431 NH2xbHJCeG:ydH;zbZMhSXO|YYm= M2HWTlIwOTBxNUCvNVAxdk1? MnXuOFhp MnHmSG1UVw>? MX7pcohq[mm2czD0bIUh[2WubDDndo94fGh? MV6yOVM4OTB4OR?=
A431 NH71OXRHfW6ldHnvckBCe3OjeR?= MYG1NI5O M{DqWlIwPi9zMj:yOIg> MXLEUXNQ NWr5VXdC[WO2aY\heIV{KHB{MTDhcoQhcW6qaXLpeJMhSVSIMzDlfJBz\XO|aX;u NH7MN48zPTN5MUC2PS=>
MDA-MB-231 Mkm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HsU|AuPjBybl2= NH\SXo8zPGh? NF\qeFVFVVOR M{PISWlEPTBib3[gNVAxdk1? MkPMNlUyQTJ5MkG=
MCF7 M4noUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PYRVAuPjBybl2= NE\SRZQzPGh? NGnF[mpFVVOR M{XDSWlEPTBib3[gO|VvVQ>? MkfsNlUyQTJ5MkG=
SKOV-3 NEHzc2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TLRVEuOTEQvF2= Mm\VNlRp NVHVXpRsTE2VTx?= NX;hUZl2UUN3MDDv[kA2NjcQvF2= NHLzWGUzPTF4OUS5NS=>
A549 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYqzXXJSOS1zMN88US=> Mk\lNlRp NULEcYdWTE2VTx?= M4XKV2lEPTBib3[gN{4z|ryP MXmyOVE3QTR7MR?=
SKOV-3 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml33NE4yNTIQvF2= MlnFOFhp MYrEUXNQ MUfJR|UxKG:oIECuO:69VQ>? NIfnRoIzPTF4OUS5NS=>
A549 MnfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;a[pljOC5zLUJOwG0> NXTrNXN1PDiq NWjzTXB5TE2VTx?= M3;lNWlEPTBib3[gNE4zQM7:TR?= NVPkS4gyOjVzNkm0PVE>
SKOV-3 NXLMZ3g5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLDNE4xOS1yLkpOwG0> M{GyXVczcA>? NHrVbWxFVVOR MYPJR|UxKG:oIECuN|LPxE1? Mmi5NlUyPjl2OUG=
A549 NEXVZYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUWwMlAyNTBwOd88US=> MoTWO|Jp NFvnTHFFVVOR NV\4V5BwUUN3MDDv[kAxNjB4zszN M{XRelI2OTZ7NEmx
HeLa MWXGeY5kfGmxbjDBd5NigQ>? NEDCeoszPTCwTR?= NGnKVYgyPmh? MWjEUXNQ MmjDbY5kemWjc3XzJGN[WDGDMTDtVm5CKGW6cILld5Nqd28EoB?= Ml3BNlUyOTZ4OEi=
CNE2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXQNVAxNTZyMH7N MUSyOE81QC95Mni= MWrpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDpckBiKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M2i5blI1QTZ7OUCx
PC3 M{DSS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPhfXEyODBvMUCwNI5O NG\jXWwzPGh? MnXDTWM2OCCxZjCzNFBvVQ>? M2LWXFI1QDV2NkW4
LNCaP NGHERpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVWxNFAuOTByMH7N MnHINlRp NWH2[ndHUUN3MDDv[kA{ODCwTR?= NX36N4pqOjR6NUS2OVg>
HeLa  MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjuNu69VQ>? MVO0PIg> NF\Ce|hl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgZYJwfXRiMkWl NEX0XnIzPDh2NkGzOS=>
HMEC-1  MWDGeY5kfGmxbjDBd5NigQ>? MkXxN|Axdk1? MVqyOIg> MmHLbY5kemWjc3XzJIV5eHKnc4Ppc44hd2cEoG\FS2ZTO8LibWLORS=> NWO5SZg4OjR5MUC2N|E>
HeLa M3i1OmZ2dmO2aX;uJGF{e2G7 MXexcW0> NUjIZ2RROC53aB?= NWLuN5Fq[WKxbHnzbIV{KHSqZTD0c5RidCCKRFHDJIFkfGm4aYT5 MV2yOFcxPzR5NB?=
ACP02 MknGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vS[FI2OC9|NUCvOVAxdk1? M1G5cVI1cA>? NWP2enlQ\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JI9nKGGycILvfIlu[XSnbImgO|DDqCViYYSgNlUxyqCwTR?= MoO0NlQ3Pjh3NEe=
ACP03 NYD5fGdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonKNlUxNzN3MD:1NFBvVQ>? MmT1NlRp M1fPZ4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDv[kBieHC{b4jpcYF1\Wy7IEewxsAmKGG2IEK1NOKhdk1? MWmyOFY3QDV2Nx?=
U87 GBM M{jvdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHoTHpXOTByL{OwNE82ODBibl2= NH7h[Xk4OiCq NWP6SJY{OTByJTDleIhidm:u MUPy[YR2[2W|IH3lZY4h[2WubDDueY1j\XJiYomgN|EtKDV2LDDhcoQhPTkEoDW= Mn;aNlQ1PjR6NEG=
U87 GBM NYLHXGl3TnWwY4Tpc44hSXO|YYm= NGHHc2QyODBxNUCwJG5u NXXleWd[PDhiaB?= NH31cIYyODBnIHX0bIFvd2x? NXvHWIxlUW6mdXPld{BU\W6nc3PlcoNmNUyra3WgRYx1\XKjdHnvcpMhcW5iToXjcIVieiCPb4LwbI9td2e7 NEDndlkzPDR4NEi0NS=>
RPE MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnzWZB{OC5{L{CuOE8xNjhxMTFOwG0> NHX5V2YzPC92OD:3NkBp NViySo13TE2VTx?= NHS3boVqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBjgSClZXzsJIN6[2ynIHHydoV{fA>? MmD3NlQ1PTZ4MEK=
HT29  M3u4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHpNVgxKG6P MWm3NkBp M32zOGlEPTBib3[gNVgxKG6P NXfxRVU1OjR|NkiyOlU>
hMSCs MWTGeY5kfGmxbjDBd5NigQ>? MWK2MlI2KG6P MYiyOEBp MlSySG1UVw>? MUHzeIFjcWyrenXzJGhqe3SxbnWgRYNmfHmuYYTpc44h[W6mIITo[UBGgHC{ZYPzbY9vKG:oIGDseZJqeG:2ZX70JGdmdmW| NUjUU5o1OjR|MUKzOVY>
Huh7  NWr3d2FkTnWwY4Tpc44hSXO|YYm= NXT6fmc2OC5zL{CuOU8yNjBizszN M3jaZ|I1cA>? MkG2d5VxeHKnc4Pld{B[XEiGQ{Kg[4Vv\SCneIDy[ZN{cW:w MVqyOFI3QTZ5Mh?=
SKOV3 NHHkV5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPXcIRzOC5yNT2yJO69VQ>? M3nzOlExNzJ2L{S4JIg> M{LNXGROW09? Mo\UcYVlcWG2ZYOg[5Jwf3SqIHHydoV{fCCrbjDhJINwdmOnboTyZZRqd25vIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? MUSyOFIzOzhyMR?=
A2780 M3\HRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLadpN[OC5yNT2yJO69VQ>? M3;GPFExNzJ2L{S4JIg> NYWwTYUxTE2VTx?= Mk\DcYVlcWG2ZYOg[5Jwf3SqIHHydoV{fCCrbjDhJINwdmOnboTyZZRqd25vIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? MVSyOFIzOzhyMR?=
SRA01/04  MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmO5NE4zKM7:TR?= MVK0PEBp MYnEUXNQ M3u5WpN2eHC{ZYPz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKHSqcn;1[4ghe3WycILld5NqdmdidHjlJHBKO0txQXv0MEBxOziPQWDLJIFv\CCHUluxM|Ihe2mpbnHsbY5oKHCjdHj3ZZl{ M{n5cFI1OTV5OEe4
HLEB3 NUW0dpRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXQfG81OC5{IN88US=> M4ftVFQ5KGh? M2DmPWROW09? NHHzdZJ{fXCycnXzd4V{KGOnbHygdJJwdGmoZYLheIlwdiC2aILveYdpKHO3cIDy[ZN{cW6pIITo[UBRUTONL1HreEwheDN6TVHQT{BidmRiRWLLNU8zKHOrZ37hcIlv\yCyYYToe4F6ew>? NH3u[3kzPDF3N{i3PC=>
SRA01/04  NVL4cHA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnreIUxNjRxMD64JO69VQ>? NUDxRpFOPDhiaB?= NUjqN5dyTE2VTx?= M{LrUIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MmDGNlQyPTd6N{i=
HLEB3 MlTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPGZlkxNjRxMD64JO69VQ>? MVu0PEBp MWnEUXNQ NYXncIxEcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MkfLNlQyPTd6N{i=
HCT116 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX6wMlIh|ryP MmrNNVIhcA>? M2fMR4VvcGGwY3XzJINmdGxiYYDvdJRwe2m|IHnu[JVk\WRiYomgdoFlcWG2aX;u NF\Cd4wzPDF{MkKzNS=>
CA46 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XlR|MwPi9zMj:yOE81QCCwTR?= NEPtVXk1QCCq M2nuT4lvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iYYSgNlQh[W6mIES4JI5OyqB? NHXIeZMzPDB4NEm1NS=>
PMNs NEXabY9HfW6ldHnvckBCe3OjeR?= M{XrO|MxKG6P M3L1d|Q5KGh? M1m3VYlvcGmkaYTzJIVn\mW{b3P5eI9{cXNuIFjERWMh[WO2aY\peJkh[W6mIGLhZ{Bi[3Srdnn0fS=> NUDncVBTOjN7OEi2NVc>
H1299 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\zOVHDqM7:TdMg MYeyOE81QC95MjDo Ml;J[ZRp[W6xbB?= M3nEZolv[3KnYYPld{Bk\WyuIHTlZZRpKGGodHXyJFI1cA>? NYLUVVlDOjN7MU[2NFk>
A549 NXXJeIZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml21NE4zPS9yLkWvNUDPxE1? MojTNlQwPDhxN{KgbC=> MUDleIhidm:u NVvRZ5pHcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJIlvKGOxbnPlcpRz[XSrb36gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NVW5[Wk3OjN6Nke5PVE>
H1299 NE\2NodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;4fYdVOC5{NT:wMlUwOSEQvF2= MWGyOE81QC95MjDo NX\OXYhm\XSqYX7vcC=> MmS3bY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHnuJINwdmOnboTyZZRqd25iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MXKyN|g3Pzl7MR?=
A549 MV;BdI9xfG:|aYOgRZN{[Xl? NFXqd2UxNjVxMTFOwG0> M1zqbVQ5KGh? NFL6bHJmfGijbn;s MX3pcoR2[2W|IHPlcIwh[XCxcITvd4l{ MoXUNlM5Pjd7OUG=
H1299 NX\0U|lJSXCxcITvd4l{KEG|c3H5 MnvuNE42NzFizszN MY[0PEBp NVe0RVE{\XSqYX7vcC=> MnvwbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MWCyN|g3Pzl7MR?=
SUM149PT MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\oblUzNzdwNT:xNEDPxE1? NUDnRZFnPDhiaB?= M{HXO2ROW09? MUnpcoR2[2W|IHPlcIwh\GWjdHigZZQhOiEQvF2gbY5{\W6|aYTpeoVtgQ>? MV2yN|c6OjZ|OB?=
SUM190PT M3PhWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrBOVAwOTByL{K1NEBvVQ>? MnzpOFghcA>? MlKwSG1UVw>? NHzYU|FqdmS3Y3XzJINmdGxiZHXheIgh[XRiNUCgcm0he2Wwc3n0bZZmdHl? MnW2NlM4QTJ4M{i=
HCT1 M{HPO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVj1PJl7OC5{L{GuNE82NjBizszN MXqxNk8zPC9|Nj:0PEBp MV3pcoR2[2W|IHPlcIwh\GWjdHigbY4h[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= M3;j[VI{PzdyMECw
Lovo MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVywMlIwOS5yL{WuNEDPxE1? M1v4eFEzNzJ2L{O2M|Q5KGh? MkTJbY5lfWOnczDj[YxtKGSnYYToJIlvKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= M{HnU|I{PzdyMECw
AGS MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoP6NE4xOTVvMTFOwG0> MXm3NkBp NE[zdHdqdmS3Y3XzJINmdGxiZHXheIgh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=> MnWxNlM4PDVyMkS=
Huh7 NXfvcHN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\OWFEh|ryP MX[yOEBp MXPEUXNQ M1TkXJJm\HWlZYOgZYJwfXRiMkClJJZq[WKrbHn0feKh M1r0eFI{PjR|OUOz
ECC1 MYXGeY5kfGmxbjDBd5NigQ>? Mn\tOVAxKG6P MWG1JIQ> NVfhRopHTE2VTx?= M1O5eIlv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF MXGyN|U{ODd4OR?=
HEC1A MX7GeY5kfGmxbjDBd5NigQ>? MV:1NFAhdk1? MUC1JIQ> MYLEUXNQ MXvpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? NEjPO3AzOzV|MEe2PS=>
EN1 NVz3eHNxTnWwY4Tpc44hSXO|YYm= M2LJO|UxOCCwTR?= MoDCOUBl NXXkb41iTE2VTx?= NFvhRXJqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= NHLLOnAzOzV|MEe2PS=>
MFE296 M3nDcmZ2dmO2aX;uJGF{e2G7 MkTwOVAxKG6P NIXXS|g2KGR? MnfESG1UVw>? NIj5VWxqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= MUKyN|U{ODd4OR?=
HASMCs NYLxbIR{TnWwY4Tpc44hSXO|YYm= MV6wMVUxOCCwTR?= NYjQ[ZlMPiCm M2S0OoRwf25vcnXneYxifGW|IITo[UBmgHC{ZYPzbY9vKG:oIFjBSGMh[W6mIHPlcIwhfmmjYnnsbZR6 M3PUNVI{PTF6NE[3
U373 M2ruOWZ2dmO2aX;uJGF{e2G7 M3r1UlAvOjVxMD61M|Eh|ryP MUCyOEBp MnPNbY5kemWjc3XzJHBTNUJiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1RZpi\EN? M4X3[VI{PDd2MUex
ARN8  MXrGeY5kfGmxbjDBd5NigQ>? MYiwMlA2NTJizszN MmLmNlQhcA>? NUj0c2t[emWmdXPld{B1cGViaX7keYN1cW:wIH;mJJA2Oy2mZYDlcoRmdnRiZ3Xu[ZMh[nliToX0cIlvNTN? NEnTcGszOzR5MEW0NC=>
MCF7 NWe1RXBYTnWwY4Tpc44hSXO|YYm= NG\2b28xNjB3LUKg{txO M3P5UlI1KGh? MnK3doVlfWOnczD0bIUhcW6mdXP0bY9vKG:oIIC1N{1l\XCnbnTlcpQh\2WwZYOgZpkhVnW2bHnuMVM> M3PqO|I{PDdyNUSw
H1299  Ml[1SpVv[3Srb36gRZN{[Xl? MnuwNE4{O+LCk{JCpOK2VQ>? NHPGOYMzPC92ODDo MlvJSG1UVw>? Mm\obY5kemWjc3XzJGUu[2GmaHXybY4heHKxdHXpckBt\X[nbIOg[I9{\SCmZYDlcoRmdnSueR?= MXqyN|Q3OTl5NR?=
H1299 NWriO4tZTnWwY4Tpc44hSXO|YYm= NX3QTW9XOC53IN88US=> MnXlOFghcA>? MWrEUXNQ MWTpcohq[mm2czD0bIUhdWmpcnH0c5J6KHCxdHXueIlidCClb33ibY5mKHerdHigd4ltcWKrbnnu NIS2SYYzOzR4MUm3OS=>
H1299 NWD4bnBiTnWwY4Tpc44hSXO|YYm= MkHqNE42KM7:TR?= MlrXOFghcA>? M3uxbGROW09? NFHIUldqdmirYnn0d{B1cGViaX72ZZNqfmWwZYPzxsAh[2:vYnnu[UB4cXSqIIPpcIljcW6rbh?= M4f4S|I{PDZzOUe1
MG-63  NInXZpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYCwMlMh|ryP MYixNk06PiCq NF;hdYFFVVOR M{m4dYlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDjc{11emWjdH3lcpQhf2m2aDDt[ZRnd3KvaX6= M4S5[FI{PDVzOEG3
LM8 MlHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPuNE4{KM7:TR?= Mn3UNVIuQTZiaB?= MVLEUXNQ NXq1VoFJcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwNXS{ZXH0cYVvfCC5aYToJI1mfG[xcn3pci=> MV2yN|Q2OThzNx?=
K562 NWLoO5pXTnWwY4Tpc44hSXO|YYm= MUiwMlUh|ryP MYeyOEBp MkSz[ZRp[W6xbB?= Mn3p[IVkemWjc3XzJJRp\SCnbor5cYUh[WO2aY\peJkhd2ZiSFTBR5Mh[29vdILlZZRu\W62IIfpeIgh[3W{Y4XtbY4> Mn\ENlM1OzB7NUe=
HEL M2O0T2Z2dmO2aX;uJGF{e2G7 NU\zZmx5OC53IN88US=> M2\ESFI1KGh? NYrRcnU2\XSqYX7vcC=> NHzlU4xl\WO{ZXHz[ZMhfGinIHXufplu\SCjY4Tpeol1gSCxZjDISGFEeyClbz30doVifG2nboSge4l1cCCldYLjeY1qdg>? M1L0[VI{PDNyOUW3
HL60 MXnBdI9xfG:|aYOgRZN{[Xl? MVOxJO69VQ>? MVyyOEBp NF\YVlRqdmS3Y3XzxsBk\WyuIHTlZZRp NV61d2ZLOjN2MEC1NVk>
KG1 MXLBdI9xfG:|aYOgRZN{[Xl? MX2xJO69VQ>? NX21PFhQOjRiaB?= M1W0U4lv\HWlZYRCpINmdGxiZHXheIg> NWfid2V[OjN2MEC1NVk>
Kazumi MljBRZBweHSxc3nzJGF{e2G7 M1\ZcFEh|ryP MlLONlQhcA>? M1\WS4lv\HWlZYRCpINmdGxiZHXheIg> NXXTZpNKOjN2MEC1NVk>
K562 M{PE[2Fxd3C2b4Ppd{BCe3OjeR?= NILxeHQyKM7:TR?= MmW4NlQhcA>? NUG0dJZ5cW6mdXPld:Kh[2WubDDk[YF1cA>? MWGyN|QxODVzOR?=
THP1 NETD[nJCeG:ydH;zbZMhSXO|YYm= MWGxJO69VQ>? MUiyOEBp MUDpcoR2[2W|wrDj[YxtKGSnYYTo MYGyN|QxODVzOR?=
SH-SY5Y NYnuNG9{TnWwY4Tpc44hSXO|YYm= NYKzRo9rOjVyIH7N Mm[xNVYhcA>? NGrCcnFkcGGwZ3XzJIV5eHKnc4Ppc44heGG2dHXyckBw\iCpZX7ld{Bqdn[xbI\l[EBqdiClaH;s[ZN1\XKxbDDzfY51cGW|aYOsJJVxfGGtZTDhcoQh\W[obIX4 M1r2SVI{OzJ4NEKy
HEK293 NGX0dJhHfW6ldHnvckBCe3OjeR?= M2PGNlEhyrWPwrC= M1TNSFE5KGkEoB?= NYnyOXhQcW6qaXLpeJMhfGinIHvhcIlzcW5vNz3t[YRq[XSnZDDy[YNzfWm2bXXueEBw\iC|eX7wbIltcW5vMTDh[4dz\WejdHXzJIlvfG9iYXfndoV{d22ncx?= MlvCNlMzQDR6NEi=
HTK M2\CWWZ2dmO2aX;uJGF{e2G7 MV[0NFAhdk1? MXK3NkBp M33vOIlvcGmkaYTzJHRITi4QsvMAl2lv\HWlZXSgUZlw\mmkcn;icIF{fCCGaX\m[ZJmdnSrYYTpc44> M2DC[|I{Ojh2MECy
HTK MWrGeY5kfGmxbjDBd5NigQ>? MlzvNVAxNThyMH7N M2PRZ|czKGh? M3nXW4Jtd2OtczDUS2Yu|rMkgKPJcoR2[2WmIGLPV{BidmRiSELPNuKhSWOldX31cIF1cW:w NEm1S|IzOzJ6NECwNi=>
Caco-2  MX3GeY5kfGmxbjDBd5NigQ>? NILmU|AyKML3TdMg M2nLPVI1KGh? MXrk[YNz\WG|ZYOgV2VTXCCycn;0[YlvKGW6cILld5Nqd25? NHX5d2szOzF7NUC3NC=>
HeLa NFr5cJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWOxNFAhdk1? M{m1WVI1KGh? MWLEUXNQ MW\JR|UxKG:oIEGwNI5O NIO1WGkzOzF4NUe0PC=>
HeLa NFrWOJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYe0NEBvVQ>? M2Pjc|Q5KGh? Mn22SG1UVw>? MWDJR|UxKG:oIESwcm0> NEfTe2YzOzF4NUe0PC=>
HeLa MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jYZlIxKG6P NI\GbnA4OiCq M1W0TWROW09? MoLvTWM2OCCxZjCyNI5O NU[4NnNjOjNzNkW3OFg>
HeLa MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rSRlExNzNyL{WwJI5O NFHmdGg4OiCq MYPEUXNQ MXLpcoNz\WG|ZYOgeIhmKG63bXLldkBw\iCPTWCgLO6V|qivKTDsc5N{KGOnbHzzJIRwe2ViZHXw[Y5l\W62bIm= M2[1bFI{OTZ3N{S4
MDA-MB-231 M3m4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHXNlUuPDByIH7N MlPlOFghcA>? MkC0TWM2OCCxZjCyOlMvOm6PwrC= M4OwN|I{ODV3MUm4
MCF-7  MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HES|I2NTRyMDDuUS=> M4fqWVQ5KGh? MUjJR|UxKG:oIEKyNE41dk1? M2flblI{ODV3MUm4
ECC-1  NEjyfYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEL5PVIyODBibl2= NWL2b4lkOjRiaB?= MlS5[ZRp[W6xbB?= NGXkVZhqdmO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4Yh[XCxcITveIlkKG63Y3zlbUB1dyB|NTW= NWfF[pBuOjNyMki4NFM>
HEC-1A NX2ySVY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrDNVAxKG6P M1;2blI1KGh? NHW5NZdmfGijbn;s MVnpcoNz\WG|ZYOgeIhmKHC{b4DvdpRqd25ib3[gZZBweHSxdHnjJI52[2ynaTD0c{A{QSV? M1n1OlI{ODJ6OECz
NHAC-kn MnPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmr1NVAwOTByL{WwNEBvVQ>? MXyxNkBp M4\pV2ROW09? M{mzNGlEPTBib3[gOVAxdk1? NGHtb48zOzBzN{i3NS=>
A549 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\DWW8zPTBibl2= NYq1ZoJZPi15MjDo NEHmeYNFVVOR MmPSZ4F2e2W|IHGg[5Jm[XSncjDpcohq[mm2b4L5JIVn\mWldDDjc41jcW6nIIfpeIghXFiWIH;yJIVzdG:2aX7pZi=> NGPDfYYzOjl7NEe4NC=>
MG-63 NHWyXm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TRWlMxOCCwTR?= NIrMOpEyOiCq MoPHSG1UVw>? MkPRbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFg3LQ>? M4\QOFIzPzl7M{O4
MG-63 M3vXO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlO4N|AxKG6P Mn7BNlQhcA>? M{DjTmROW09? M4XaS4lvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A3PyV? MkW1NlI4QTl|M{i=
MG-63 MmHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWqzNFAhdk1? M1rWbFQ5KGh? NXu5R4drTE2VTx?= M17XdolvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A2PiV? NHnCTlgzOjd7OUOzPC=>
HL60  NIezVmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXSxOVAuOzVyIH7N MYWyOEBp M4rSTYlv[3KnYYPld{Bk\WyuIHHwc5B1d3Orc9Mge4hmdiClb37j[Y51emG2aX;ud{BpcWeqZYKgeIhidiB{NUCgcm0> MlruNlI4PTN5M{m=
U937 NGCxT2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX6xOVAuOzVyIH7N NUPybI5ZOjRiaB?= M3jm[Ylv[3KnYYPld{Bk\WyuIHHwc5B1d3Orc9Mge4hmdiClb37j[Y51emG2aX;ud{BpcWeqZYKgeIhidiB{NUCgcm0> MW[yNlc2Ozd|OR?=
SCC-6 M3TwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHWNlAxNTN{MECgcm0> M1G4d|EzNzJ2L{S4JIg> NHXuVFRFVVOR NH7NOmVqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBw\iCVQ1OtOkBk\WyuczDpckBiKGSxc3WtJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NHvxNWczOjV3MkOyNS=>
U87  M1Hy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17POFExOC1|MECgcoc> M2jLdVI1KGh? NXr5[lRucW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDd{JTCgZZQhOjBybne= M{PvbVIzOjdyOES5
K562 MXzGeY5kfGmxbjDBd5NigQ>? NG\1[ZkyKM7:TR?= MoDHNVIhcA>? Ml7LSG1UVw>? M1zrXYVvcGGwY3XzJJRp\SCneIDy[ZN{cW:wIH;mJHJWVlh|IHnu[JVk\WRiYomgOU1igmFvQ3TS MnfPNlIyPzlzOUi=
Reh NVTRT4RbTnWwY4Tpc44hSXO|YYm= NHfrWXQxNjNxMTFOwG0> M33zZVEzKGh? NV\CSnlETE2VTx?= NYqxNWhJ\W6qYX7j[ZMhfGinIHX4dJJme3Orb36gc4YhWlWQWEOgbY5lfWOnZDDifUA2NWG8YT3D[HI> NHjzbYszOjF5OUG5PC=>

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
EGFR / STAT3 ; 

PubMed: 31289542     


Expression of EGFR and STAT3 in PC3 cells treated with TSA. PC3 cells were plated in 6-cm dishes, and 0.25, 0.5 or 1 µM TSA was added for 24 h. DMSO was added into the control group wells. Cells were collected and lysed with lysis buffer and the protein expression analyzed via western blotting.

Cyclin D1 / CDK6 / CDK4 / p-RB / RB; 

PubMed: 31289542     


Expression of cyclin D1, CDK6, CDK4 and RB, and the phosphorylation of RB, was detected in PC3 cells treated with TSA for 24 h. 

MMP-1 / MMP-3 / MMP-13 / TIMP-1; 

PubMed: 27431944     


Chondrocytes were pretreated with increasing concentrations of TSA for 2 h, followed by stimulation with 5 ng/ml IL-1β for 24 h.

Acetyl-H3 (Lys27) / H3 (96C10) / Acetyl-H4(Lys8) / H4(L64C1); 

PubMed: 27431944     


Chondrocytes were treated with increasing concentrations of TSA for 24 h.

α-H3Ac / α-H4Ac / α-H3K9Ac / α-H3K9 S10 / α-H3K4 me / α-H3K4 me2 / α-H3K9 me2; 

PubMed: 23802098     


Histone acetylation occurs directly at the promoter region of IL-23R. The ChIP assay demonstrates that TSA treatment results in an increase in the acetylation of histone H3 and H4. A549 cells were cultured in the presence or absence of TSA (250 ng/mL) for a period of 24 h. Subsequently, a ChIP assay was performed using the following antibodies; pan acetyl-histone H3 (H3Ac), pan acetyl-histone H4 (H4Ac), acetyl-histone H3 Lys 9 (H3K9Ac), acetyl-histone H3 Lys 9/14 (H3K9/14ac), acetyl-histone H3 Lys 9 phosphoSer10 (H3K9S10), methyl-histone H3 Lys 4 (H3K4Me), di methyl-histone H3 Lys 4 (H3K4Me2), and di methyl-histone H3 Lys 9 (H3K9Me2). Input DNA serves as a positive control as recommended by the manufacturer (Diagenode). A no antibody control was included to test for non-specific binding (UT, untreated; TSA, Trichostatin A).

31289542 27431944 23802098
Immunofluorescence
α-C/EBPβ / α-HP1α ; 

PubMed: 21122806     


3T3-L1 preadipocytes were grown on coverslips for three days and induced to differentiate by treatment with MDI (48 h) in the presence of vehicle (-TSA) or 87 nM Trichostatin A (+TSA). Under these experimental conditions: A-H Cells were fixed and permeabilized in cold methanol, subjected to IIF with the indicated antibodies, and nuclei were counterstained with DAPI. Scale bar, 5 μm. 

α-HDAC1 ; 

PubMed: 29045501     


MCF-7 cells were treated with indicated concentrations of trichostatin A (optical sections E-H, respectively) for 12 hours, fixed, permeabilized and optical sections were obtained by laser scanning confocal microscopy. Fluorescence signal for HDAC1 is shown in green (left panels), DAPI staining is shown in blue (middle panels), and merged optical sections are shown in the right panels.

α-tubulin / acetylated histone 3; 

PubMed: 27957719     


Immunocytochemistry for acetylated α-tubulin (red) and acetylated histone 3 (green) on N2a cells treated with 1 μM TSA, ACY-738, and ACY-775.

21122806 29045501 27957719
Growth inhibition assay
Cell viability (A549 cells); 

PubMed: 27571418     


Cytotoxicity of histamine determined by MTT assay in A549 cells.

Cell viability (MDA-MB-231 cells); 

PubMed: 27548148     


The human breast cancer cells (MDA-MB-231) were incubated with various concentrations of TSA (0–300 nM) for 24 h. Cell viability was measured by WST-8.

Cell viability (PC3 cells); 

PubMed: 31289542     


PC3 cells were plated in a 96-well plate and treated with different doses of TSA (0, 0.25, 0.5 and 1 µM) for 72 h; an MTT assay was used to measure the effects of TSA on PC3 cell proliferation.

27571418 27548148 31289542
体内研究 Administration of Trichostatin A 按 0.5 mg/kg 剂量处理N-甲基-N-亚硝基脲致癌物诱发的大鼠乳腺癌模型，持续处理4周，具有有效的抗癌活性，即使按按高达5 mg/kg剂量处理也没有任何可测量到的毒性。[1]Trichostatin A 按10 mg/kg 剂量单独腹腔注射给药非转基因和脊髓性肌萎缩症（SMA）模型鼠，导致乙酰化的 H3 和 H4组蛋白水平提高，也导致活运动神经元(SMN) 基因表达稍微提高。Trichostatin A 每天按10 mg/kg剂量处理SMA模型鼠，促进存活, 减轻体重下降,且增强运动行为。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验：[1]
+ 展开

体外HDAC活性 :

从每种乳腺癌细胞系(MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51,或 SK-BR-3)中准备全部细胞提取物。在溶于0.1% (v/v)乙醇的不同浓度Trichostatin A存在时，或者使用0.1% (v/v)乙醇作为对照, 20 μL 细胞粗提取物(~2.5 ×105 个细胞)与 1 μL ~1.5 × 106 cpm [3H]乙酰标记的组蛋白 H4 肽底物(第2-20位NH2-末端残基) 在25oC下温育60分钟。使用50 μL 1 M HCl/0.16 M 乙酸对每组 200-μL 反应进行淬火，然后使用600 μL 乙酸乙酯进行抽提，通过闪烁计数器测量释放的[3H]乙酸。使用非线性回归曲线拟合抑制数据，绘制合适的剂量反应曲线，而测定IC50。
细胞实验：[1]
+ 展开
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, 和 SK-BR-3
  • Concentrations: 溶于无水酒精,终浓度为~10 μM
  • Incubation Time: 96小时
  • Method: 使用不同浓度Trichostatin A处理细胞96小时。处理后,使用sulforhodamine B 比色分析测定细胞增殖。通过台酚蓝染色排除法测定细胞活力。
    (Only for Reference)
动物实验：[1]
+ 展开
  • Animal Models: 携带NMU诱导的肿瘤的近交系(Ludwig/Wistar/Olac)处女鼠
  • Formulation: 溶于DMSO
  • Dosages: ~5 mg/kg/day
  • Administration: 皮下注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)：
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
 3mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 302.4
化学式

C17H22N2O3
CAS号 58880-19-6
储存条件 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03901053 Not yet recruiting Foot Injuries and Disorders Jason Wilken|Minneapolis Veterans Affairs Medical Center|Walter Reed National Military Medical Center|Henry M. Jackson Foundation for the Advancement of Military Medicine|Center for Veterans Research and Education|University of Delaware|Johns Hopkins Bloomberg School of Public Health|University of Iowa June 2019 Not Applicable
NCT03887650 Recruiting Post-operative Pain|Total Shoulder Arthroplasty|Osteoarthritis of the Shoulder|Pain Management Hartford Hospital January 14 2019 Phase 4
NCT03838926 Recruiting Relapsed or Refractory Hematologic Malignancies Vanda Pharmaceuticals September 27 2018 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1：

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • 回答：

    Our S1045 Trichostatin A (TSA) is R enantiomer.

Selleck产品目录册

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品

  • LMK-235 New

    LMK-235是HDAC4和HDAC5的选择性抑制剂， IC50分别为11.9 nM 和 4.2 nM。

  • CAY10603 New

    CAY10603是一种强效的选择性HDAC6抑制剂，IC50为2 pM，选择性比其它HDACs高200多倍。

  • Domatinostat (4SC-202) New

    4SC-202是一种选择性的I类HDAC抑制剂，对HDAC1，HDAC2，和HDAC3的IC50分别为1.20 μM，1.12 μM，和0.57 μM。也对Lysine specific demethylase 1 (LSD1)表现出抑制活性。Phase 1。

  • Panobinostat (LBH589)

    Panobinostat (LBH589)是一种新型的，广谱HDAC抑制剂，无细胞试验中IC50为5 nM。Phase 3。

  • Vorinostat (SAHA, MK0683)

    Vorinostat (suberoylanilide hydroxamic acid, SAHA)是一种HDAC抑制剂，无细胞试验中IC50为~10 nM。

    Features:Vorinostat是广谱HDAC活性抑制剂，抑制I和II类酶 。

  • Entinostat (MS-275)

    Entinostat (MS-275)强烈抑制HDAC1和HDAC3，无细胞试验中IC50分别为0.51 μM和1.7 μM，抑制作用强于HDACs 4， 6， 8，和10。Phase 3。

  • Romidepsin (FK228, Depsipeptide)

    Romidepsin (FK228, Depsipeptide)是一种有效的HDAC1和HDAC2抑制剂，无细胞试验中IC50分别为36 nM和47 nM。

    Features:Romidepsin对I型HDAC的抑制作用明显强于对II型HDAC的抑制。

  • RGFP966

    RGFP966是一种HDAC3抑制剂，无细胞试验中IC50为0.08μM ，比作用于其他HDAC选择性高200倍以上。

  • Tubastatin A

    Tubastatin A是一种有效的，选择性HDAC6抑制剂，无细胞试验中IC50为15 nM，选择性远高于所有其他同工酶(1000倍)除了HDAC8(57倍)。

  • Mocetinostat (MGCD0103)

    Mocetinostat (MGCD0103)是一种有效的HDAC抑制剂，对HDAC1抑制作用最强，无细胞试验中IC50为0.15 μM，比作用于HDAC2， 3，和11选择性高2到10倍，对HDAC4， 5， 6， 7，和8没有抑制活性。Phase 2。

Tags: 购买Trichostatin A (TSA) | Trichostatin A (TSA)供应商 | 采购Trichostatin A (TSA) | Trichostatin A (TSA)价格 | Trichostatin A (TSA)生产 | 订购Trichostatin A (TSA) | Trichostatin A (TSA)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID